Last updated: September 3, 2026
AZOPT, the branded ophthalmic suspension of brinzolamide 1%, is a mature glaucoma product with limited remaining exclusivity value. FDA approval dates to 1998, the original patent estate has aged beyond the primary commercial protection period, and the product competes with generic brinzolamide, dorzolamide, prostaglandin analogs, beta blockers, and fixed-dose combinations. Alcon owns the commercial brand following its separation from Novartis, but AZOPT revenue is not separately reported in recent public financial filings. Its future financial trajectory is therefore driven by prescription retention, payer substitution, generic pricing, and ophthalmology portfolio strategy rather than by patent-protected growth.
What is AZOPT and how does it work?
AZOPT is the trade name for brinzolamide ophthalmic suspension 1%. It is a topical carbonic anhydrase inhibitor used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Brinzolamide inhibits carbonic anhydrase II in the ciliary processes of the eye. This reduces bicarbonate formation and aqueous humor production, lowering intraocular pressure. The FDA-approved regimen is generally one drop in the affected eye three times daily, either as monotherapy or in combination with other intraocular-pressure-lowering treatments. The suspension must be shaken before use. [1]
| Attribute |
AZOPT |
| Active ingredient |
Brinzolamide |
| Strength |
1% ophthalmic suspension |
| Therapeutic category |
Glaucoma and ocular hypertension |
| Drug class |
Topical carbonic anhydrase inhibitor |
| Original sponsor |
Alcon Laboratories |
| FDA application |
NDA 020816 |
| Initial FDA approval |
1998 |
| Administration |
Topical ophthalmic |
| Main alternatives |
Dorzolamide, timolol, latanoprost, bimatoprost, travoprost, fixed combinations |
| Biologic status |
Small-molecule drug |
| Biosimilar exposure |
None |
AZOPT differs from dorzolamide ophthalmic solution in formulation and tolerability profile. Brinzolamide is formulated as a suspension, while dorzolamide is generally supplied as a solution. Both products require multiple daily administrations and compete mainly in the adjunctive and alternative-treatment segments of glaucoma care.
What is the FDA regulatory status of AZOPT?
AZOPT remains an FDA-approved prescription ophthalmic product. Its regulatory status is that of a mature small-molecule drug rather than a biologic. It does not qualify for biosimilar protection or face biosimilar competition.
The core FDA regulatory milestones are:
| Milestone |
Date or status |
| FDA approval |
1998 |
| NDA |
020816 |
| Dosage form |
Ophthalmic suspension |
| Strength |
1% |
| Approval pathway |
Full NDA |
| Regulatory exclusivity |
Expired |
| Current competitive pathway |
ANDA generic substitution |
| Pediatric exclusivity |
No material current commercial effect |
AZOPT’s clinical value is established, but its regulatory profile no longer creates a meaningful barrier to generic entry. For a product approved in 1998, statutory periods of new chemical entity exclusivity and any original regulatory exclusivity have expired. The commercial question is therefore whether generic manufacturers can meet the FDA’s requirements for formulation equivalence, particle size, suspension behavior, sterility, and ophthalmic product performance.
What patents protect AZOPT and when did exclusivity expire?
AZOPT’s principal patent protection has expired or is no longer commercially material. The foundational brinzolamide patent family was filed in the late 1980s and early 1990s, placing ordinary U.S. patent expiry well before the current market period. FDA patent records and historical product literature identify brinzolamide composition and ophthalmic formulation patents associated with Alcon and its predecessor entities. [2][3]
The key protection periods were:
| Protection category |
Commercial relevance |
| Brinzolamide compound patents |
Expired |
| Original ophthalmic formulation patents |
Expired or outside the primary exclusivity window |
| FDA new chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Method-of-use patents |
Limited current blocking value |
| Device or packaging rights |
Potentially relevant only to specific presentations |
| Trade name AZOPT |
Trademark protection remains separate from drug exclusivity |
The most important distinction is between patent expiry and trademark survival. Alcon can continue marketing AZOPT under the AZOPT name even after generic brinzolamide products enter the market. The trademark does not prevent FDA-approved generic manufacturers from selling brinzolamide ophthalmic suspension.
Does AZOPT have formulation or method-of-use protection?
Formulation patents were historically important because ophthalmic suspensions must maintain uniform dosing, sterility, particle-size control, comfort, and physical stability. Those properties can make generic development more difficult than a conventional oral tablet.
The practical protection value is limited today. A generic applicant does not need to copy every commercial attribute of AZOPT. It must demonstrate pharmaceutical equivalence and bioequivalence under the FDA’s applicable ophthalmic standards, while avoiding any unexpired listed patent claims. A different excipient system, manufacturing process, container, or suspension technology may reduce infringement exposure.
Method-of-use protection is also limited. AZOPT’s principal use is lowering intraocular pressure in ocular hypertension and open-angle glaucoma, a broad and established indication. Broad treatment claims of this type are difficult to preserve as an effective late-life barrier once the compound and product patents have expired.
What is the Orange Book status of AZOPT?
AZOPT is associated with FDA NDA 020816. The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the controlling source for current patent listings, regulatory exclusivity, and therapeutically equivalent products. [2]
The business implications are straightforward:
- AZOPT’s Orange Book position is no longer equivalent to a protected launch product.
- Any current listed patent must be assessed claim by claim and against its expiry date.
- A generic applicant can file an ANDA with a Paragraph III certification if all listed patents have expired, or a Paragraph IV certification if it asserts that a listed patent is invalid, unenforceable, or not infringed.
- The absence of meaningful current exclusivity increases substitution risk.
Because FDA Orange Book listings can change through delisting, expiry, or administrative updates, current patent conclusions should be tied to the latest NDA 020816 entry rather than to historical patent summaries.
Which companies challenge AZOPT through generic competition?
AZOPT competes with both branded therapies and generic brinzolamide. The relevant competitive set includes:
| Competitor |
Active ingredient or class |
Competitive impact |
| Generic brinzolamide |
Brinzolamide 1% |
Direct substitution |
| Trusopt and generic dorzolamide |
Dorzolamide |
Same therapeutic class |
| Timoptic and generic timolol |
Beta blocker |
Low-cost alternative |
| Xalatan and generic latanoprost |
Prostaglandin analog |
Common first-line therapy |
| Lumigan and generic bimatoprost |
Prostaglandin analog |
Efficacy and brand competition |
| Travatan Z and generic travoprost |
Prostaglandin analog |
Alternative prostaglandin |
| Cosopt and generic dorzolamide/timolol |
Fixed combination |
Adherence and convenience advantage |
| Simbrinza |
Brinzolamide plus brimonidine |
Combination-product competition |
| Rocklatan and Rhopressa |
Rho kinase-based products |
Newer branded options |
Generic competition may come from multiple ANDA sponsors over time. The commercial threat is not limited to a single entrant because brinzolamide ophthalmic suspension can become a multi-source product once FDA approval and manufacturing capacity are established.
How strong is the AZOPT patent estate?
AZOPT has a weak current patent position and a moderate historical formulation moat.
Historical strength
The original estate protected:
- The brinzolamide active pharmaceutical ingredient.
- Ophthalmic use in reducing intraocular pressure.
- Suspension formulations.
- Certain excipient and delivery characteristics.
These rights supported the branded product during its early commercial period. They are no longer sufficient to preserve monopoly pricing.
Current strength
The current estate has limited ability to prevent generic entry because:
- Core compound protection has expired.
- Regulatory exclusivity has expired.
- Glaucoma indications are established and difficult to monopolize broadly.
- Generic ophthalmic manufacturers have experience with suspension products.
- Prescribers have multiple low-cost alternatives.
- Payers can encourage substitution through formulary tiering.
Residual protection may still exist around a particular formulation, container, manufacturing process, or presentation. That protection would be narrower than the original product monopoly and would not necessarily block all brinzolamide competition.
When did AZOPT lose exclusivity?
AZOPT lost its primary exclusivity well before the current decade. The product was approved in 1998, and the relevant compound and product-protection periods have run their statutory course. The key commercial transition occurred when generic brinzolamide became available or commercially viable, allowing pharmacies and payers to substitute a lower-cost equivalent.
Unlike a product with an unexpired patent cliff in the near term, AZOPT is already in the post-exclusivity phase. Its revenue erosion is therefore expected to be gradual or continuing rather than concentrated in a future single expiry event.
The exact timing of generic erosion depends on:
- FDA approval dates for individual ANDAs.
- Number of approved manufacturers.
- Wholesale acquisition cost and rebate strategies.
- State-level substitution rules.
- Formulary placement.
- Physician preference for the branded suspension.
- Availability of combination therapies.
What is AZOPT’s financial trajectory?
Alcon does not generally report AZOPT as a standalone revenue line in its public annual reporting. The company reports broader ophthalmic pharmaceutical and vision-care categories, which prevents a precise public calculation of AZOPT sales, operating margin, or year-over-year revenue decline. [4]
The product’s financial trajectory can nevertheless be assessed from its market structure.
Revenue profile
AZOPT revenue is likely characterized by:
- Mature or declining prescription volume.
- Higher average selling price than generic brinzolamide.
- Increasing gross-to-net pressure from rebates and payer concessions.
- Lower strategic importance within Alcon’s broader ophthalmic portfolio.
- Greater dependence on brand loyalty and prescriber inertia.
- Reduced contribution from patent-based pricing power.
The economic value of AZOPT is now concentrated in residual branded demand, distribution relationships, and portfolio cross-selling rather than exclusivity.
Margin profile
Branded ophthalmic products can maintain attractive gross margins after patent expiry if the brand retains a meaningful share and manufacturing costs are low relative to price. Those margins typically compress as:
- Generic products gain formulary preference.
- Wholesalers and pharmacy benefit managers demand discounts.
- Multiple generic suppliers compete on price.
- Physicians become more comfortable with generic substitution.
- The brand requires promotional spending to defend share.
AZOPT’s suspension formulation may support some persistence because patients and physicians can perceive differences in bottle design, comfort, consistency, or tolerability. That retention effect can slow erosion but does not remove price pressure.
Scenario analysis
| Scenario |
Market outcome |
Financial effect |
| Brand retention |
AZOPT keeps a niche among patients stable on therapy |
Gradual revenue decline; margins remain above generic levels |
| Broad substitution |
Payers and pharmacies substitute generic brinzolamide |
Rapid price and volume erosion |
| Combination-product migration |
Patients move to fixed-dose or multi-agent therapy |
AZOPT loses monotherapy and adjunctive volume |
| Supply disruption |
Generic shortages or quality issues preserve brand demand |
Temporary volume recovery |
| Portfolio rationalization |
Alcon reduces promotion or distribution support |
Faster decline and possible channel contraction |
The base-case commercial view is continued erosion with a residual branded tail. A major revenue rebound is unlikely without a new indication, improved delivery system, or commercial repositioning.
What licensing deals affect AZOPT?
AZOPT originated from Alcon’s ophthalmic pharmaceutical operations and later became part of Novartis’ Alcon business. Alcon was separated from Novartis in 2019 and became an independent public company. [5]
There is no widely disclosed current licensing transaction that creates a new exclusivity period for AZOPT. Historical corporate ownership is more important than a continuing third-party license:
| Period |
Corporate context |
| Original development and commercialization |
Alcon |
| 2011-2019 |
Alcon operated within Novartis |
| 2019 onward |
Alcon operated as an independent company |
Any manufacturing, distribution, or regional commercialization arrangements would need to be distinguished from a patent license. A commercial supply agreement does not restore expired compound exclusivity.
What patent litigation and Paragraph IV risk affect AZOPT?
AZOPT is primarily exposed to historical or potential generic-entry litigation rather than to a current high-value patent cliff. Paragraph IV risk would arise if an ANDA applicant challenged any unexpired Orange Book-listed patent associated with NDA 020816.
The main litigation variables are:
- Whether any listed patent remains unexpired.
- Whether the generic applicant uses a Paragraph IV certification.
- Whether Alcon files suit within the statutory 45-day period.
- Whether a 30-month stay applies.
- Whether the challenged claims cover the generic’s suspension, container, or manufacturing method.
- Whether the parties settle before approval or launch.
A Paragraph IV filing does not guarantee a launch. The generic applicant may launch at risk, wait for litigation resolution, or pursue a non-infringing formulation. For a mature product with limited remaining claim scope, the expected litigation value is generally lower than for a recently approved branded medicine.
No current settlement arrangement should be assumed without reviewing the relevant FDA records, court docket, and agreement disclosures. Settlement economics would depend on whether Alcon could offer an authorized-generic arrangement, a delayed launch date, or commercial supply terms.
What generic launch risks exist for AZOPT?
The principal generic launch risk is substitution at the pharmacy level rather than a sudden loss of all demand. Brinzolamide is a chronic-use ophthalmic medicine, so patients may remain on AZOPT if they are stable and tolerating it. New prescriptions are more vulnerable to generic substitution.
Risk increases when:
- Multiple ANDA products receive FDA approval.
- Generic products obtain an FDA therapeutic-equivalence rating.
- Major payers place generic brinzolamide on the preferred tier.
- Pharmacies hold reliable generic inventory.
- Generic products match AZOPT’s bottle usability and suspension performance.
- Physicians prescribe by active ingredient rather than brand.
Risk is lower when patients experience intolerance, preservative sensitivity, adherence problems, or a perceived difference in ocular comfort after switching.
How does AZOPT compare with competing glaucoma drugs?
AZOPT has a weaker commercial position than first-line prostaglandin analogs and a more defensible niche than a simple low-cost generic tablet because ophthalmic suspensions involve formulation and usability considerations.
| Product group |
Typical commercial position |
AZOPT implication |
| Prostaglandin analogs |
Common first-line therapy; once-daily dosing |
AZOPT loses on convenience |
| Timolol |
Low-cost and widely available |
Strong price competition |
| Dorzolamide |
Direct class substitute |
High therapeutic substitution |
| Brinzolamide/timolol combinations |
Fewer bottles and doses |
Threat to adjunctive use |
| Brinzolamide/brimonidine combination |
Branded combination option |
Can reduce separate AZOPT prescriptions |
| Rho kinase inhibitors |
Newer branded alternatives |
Premium competition in selected patients |
AZOPT’s main advantages are established clinical use, physician familiarity, and the possibility of better tolerability for some patients than dorzolamide. Its main disadvantages are three-times-daily dosing, suspension handling, generic substitution, and competition from once-daily therapies.
What geographic markets remain commercially relevant?
The United States remains important because FDA-approved generic substitution can rapidly affect brand volume and pricing. Europe and other regulated markets also face generic competition after patent expiry, but market erosion varies according to national reimbursement systems, reference pricing, tendering, and physician prescribing rules.
Geographic commercial value depends on:
- Local patent expiry and supplementary protection rights.
- National marketing authorization status.
- Reimbursement policy.
- Pharmacy substitution rules.
- Local generic manufacturing capacity.
- Distribution and supply continuity.
- Preservative and formulation requirements.
A brand may retain a higher share in markets where substitution is restricted or where physicians control product selection. In tender-driven systems, price erosion can be faster.
Key Takeaways
- AZOPT is brinzolamide 1% ophthalmic suspension for ocular hypertension and open-angle glaucoma.
- FDA approval dates to 1998 under NDA 020816.
- AZOPT is a mature, post-exclusivity product with no biosimilar exposure.
- Core compound and original product-protection periods no longer provide a meaningful commercial barrier.
- Generic brinzolamide is the principal direct threat, while dorzolamide, prostaglandin analogs, timolol, and fixed combinations expand substitution pressure.
- Alcon does not separately disclose AZOPT revenue, so product-level financial performance cannot be isolated from public company filings.
- The likely financial trajectory is continuing revenue and margin erosion with a residual branded tail.
- Remaining value lies in brand recognition, physician familiarity, formulation tolerability, and supply reliability.
- Current Paragraph IV and litigation exposure depends on the latest Orange Book listing for NDA 020816 and any unexpired formulation or manufacturing claims.
- AZOPT is unlikely to generate material growth without new formulation, delivery, or indication-based differentiation.
FAQs
Is AZOPT still sold in the United States?
AZOPT remains an established prescription ophthalmic brand associated with Alcon, although availability and commercial distribution can vary by channel and market.
Is generic brinzolamide equivalent to AZOPT?
FDA-approved generic brinzolamide products are required to meet applicable standards for pharmaceutical equivalence and therapeutic equivalence. Patients may still perceive differences in suspension behavior, bottle design, or tolerability.
Can AZOPT be substituted automatically at the pharmacy?
Substitution depends on the generic product’s FDA therapeutic-equivalence rating and the pharmacy-substitution rules of the applicable state or country.
Does AZOPT have pediatric exclusivity?
Any original pediatric exclusivity associated with the product would have expired and has no current ability to delay generic competition.
Is brinzolamide a high-growth ophthalmology product?
No. Brinzolamide is a mature glaucoma therapy. Its market is primarily defensive and maintenance-oriented, with growth constrained by generic competition, established alternatives, and the availability of fixed-dose combinations.
References
- U.S. Food and Drug Administration. (2015). AZOPT (brinzolamide ophthalmic suspension) prescribing information. Alcon Laboratories, Inc. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Patent and Trademark Office. (n.d.). Patent Center and patent assignment records. https://patentcenter.uspto.gov/
- Alcon Inc. (2024). Annual report and Form 10-K. https://investor.alcon.com/financial-information/annual-reports
- Novartis AG. (2019). Completion of the Alcon spin-off. https://www.novartis.com/news/media-releases/novartis-completes-spin-alcon-spinoff
